Article Text

Download PDFPDF
Review: α glucosidase inhibitors improve glycaemic control but have uncertain effects on patient-important outcomes in type 2 diabetes

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with type 2 diabetes mellitus, are α glucosidase inhibitors effective for improving glycaemic control?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★☆☆ Endocrine ★★★★★☆☆


Embedded ImageData sources:

Medline (to April 2003), EMBASE/Excerpta Medica (to April 2003), the Cochrane Central Register of Controlled Trials (Issue 3, 2003), LILACS (to April 2003), databases of ongoing trials (all to April 2003), Current Contents (to December 2003), contacting experts and manufacturers, and bibliographies of relevant studies.

Embedded ImageStudy selection and assessment:

randomised controlled trials (RCTs) in any language with ⩾12 weeks’ duration that compared α glucosidase inhibitor monotherapy with any other intervention in patients with type 2 diabetes and included …

View Full Text


  • For correspondence: Dr F Van de Laar, University Medical Centre Nijmegen, Nijmegen, The Netherlands. f.vandelaar{at}

  • Source of funding: no external funding.